Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 4.35Sun Pharma Advanced Research Company Ltd, operating within the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strong solvency and some positive growth indicators, particularly in operating profit and EPS. However, it struggles with liquidity, efficiency, coverage, financial metrics, and profitability. Revenue and asset growth have declined, and key profitability margins are significantly negative. The company's high solvency score is contrasted by poor liquidity and profitability, suggesting potential challenges in meeting short-term obligations and generating profit from its operations. Overall, while there are areas of strength, significant improvements are needed to ensure long-term financial stability and growth.
Health Score : 4.35Sun Pharma Advanced Research Company Ltd, operating within the Healthcare Services sector, demonstrates a mixed financial performance. The company shows strong solvency and some positive growth indicators, particularly in operating profit and EPS. However, it struggles with liquidity, efficiency, coverage, financial metrics, and profitability. Revenue and asset growth have declined, and key profitability margins are significantly negative. The company's high solvency score is contrasted by poor liquidity and profitability, suggesting potential challenges in meeting short-term obligations and generating profit from its operations. Overall, while there are areas of strength, significant improvements are needed to ensure long-term financial stability and growth.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
4.12
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
4.12
P/B RATIO
4.77
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
3.13
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
3.69
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹196.98 as on Sep 1, 2026.
Growth Score : 7.20The company exhibits mixed growth signals. While operating profit and EPS growth are positive, revenue and asset growth have declined. This suggests that while the company is improving its profitability, it struggles to expand its revenue base and asset portfolio. Continued focus on innovation and market expansion is crucial for sustained growth.
Revenue Growth RatePoorOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RatePoorNet Income Growth RateExcellent| Growth Ratios | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Revenue Growth Rate | -68.2 | -5.26 | 2509.72 |
| Operating Profit Growth Rate | -87.85 | 19.65 | 595.05 |
| Earnings Per Share (EPS) Growth | -73.91 | 11.57 | 553.65 |
| Asset Growth Rate | -37.95 | -34.76 | 546.13 |
| Net Income Growth Rate | -73.54 | 11.37 | 552.77 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | AMRUTANJAN | 8.25 | 70.69 | Highly Overvalued | 31.00 | 20.03 | 21.00 |
| 2 | FDC | 7.64 | 19.29 | Neutral | 346.00 | 17.56 | 281.00 |
| 3 | SUPRIYA | 7.46 | 30.91 | Overvalued | 294.00 | 25.98 | 209.00 |
| 4 | AARTIPHARM | 7.46 | 44.90 | Neutral | 369.00 | 19.43 | 175.00 |
| 5 | INNOVACAP | 7.36 | 43.37 | Overvalued | 243.00 | 14.63 | 141.00 |
| 6 | AKUMS | 7.28 | 48.06 | Overvalued | 522.00 | 7.09 | 256.00 |
| 7 | AARTIDRUGS | 7.20 | 20.00 | Undervalued | 309.00 | 18.54 | 195.00 |
| 8 | HIKAL | 7.13 | -50.14 | Neutral | 220.00 | -3.95 | -49.00 |
| 9 | RPGLIFE | 7.12 | 37.20 | Neutral | 147.00 | 69.64 | 115.00 |
| 10 | MOREPENLAB | 7.12 | 59.91 | Neutral | 126.00 | 1.21 | 96.00 |
| 11 | ALEMBICLTD | 7.06 | 8.00 | Undervalued | 90.00 | 4.85 | 317.00 |
| 12 | SMSPHARMA | 5.94 | 33.82 | Neutral | 171.00 | 9.35 | 102.00 |
| 13 | SHILPAMED | 5.94 | 71.52 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 14 | GUFICBIO | 5.49 | 65.79 | Neutral | 151.00 | 6.30 | 64.00 |
| 15 | DCAL | 5.38 | 29.23 | Neutral | 566.00 | -2.45 | 97.00 |
| 16 | IOLCP | 5.31 | 40.61 | Neutral | 269.00 | 4.69 | 138.00 |
| 17 | INDOCO | 5.26 | -23.65 | Neutral | 142.00 | -0.61 | -99.00 |
| 18 | ORCHPHARMA | 4.85 | 234.05 | Neutral | 41.00 | 8.91 | 21.00 |
| 19 | SEQUENT | 4.61 | 301.49 | Overvalued | 162.00 | 1.74 | 32.00 |
| 20 | SPARC | 4.35 | 4.12 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 21 | SOLARA | 4.34 | -313.88 | Neutral | 187.00 | -1.50 | -7.00 |
| 22 | ZOTA | 3.97 | -48.15 | Neutral | 19.00 | 8.06 | -74.00 |
| 23 | NOVARTIND | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 1 Technical Indicators From The 1 Hour Timeframe
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
No Stock News Available at This Moment.
Sun Pharma Advanced Research Company Ltd (SPARC) is a pure-play pharmaceutical R&D company focused on discovering and developing novel chemical entities (NCEs) and innovative drug delivery systems (NDDS). It leverages advanced scientific approaches to create differentiated products, primarily for its promoter, Sun Pharmaceutical Industries Ltd., aiming to address unmet medical needs.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Sun Pharma Advanced Research Company Ltd's P/E ratio (TTM) is 4.12, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Sun Pharma Advanced Research Company Ltd's P/B ratio is 4.77, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Sun Pharma Advanced Research Company Ltd's P/S ratio is 3.13, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Sun Pharma Advanced Research Company Ltd's PEG ratio is N/A.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Sun Pharma Advanced Research Company Ltd's EV/EBITDA ratio is 3.69.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Sun Pharma Advanced Research Company Ltd's ROE is 116.07%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Sun Pharma Advanced Research Company Ltd's ROA is 73.65%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Sun Pharma Advanced Research Company Ltd's ROCE is 164%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Sun Pharma Advanced Research Company Ltd's operating margin is 85.10%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Sun Pharma Advanced Research Company Ltd's net margin is 82.65%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Sun Pharma Advanced Research Company Ltd's current ratio is 2.43.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Sun Pharma Advanced Research Company Ltd's debt-to-equity ratio is 0.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Sun Pharma Advanced Research Company Ltd's interest coverage ratio is 46.68.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Sun Pharma Advanced Research Company Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Sun Pharma Advanced Research Company Ltd's EPS is 553.65.
(Source line: "Ratios as of 01 Sept 2026, based on last traded price of ₹196.98. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2006
Headquarters: Mumbai, Maharashtra
Core Offerings: Novel Chemical Entities (NCEs), Novel Drug Delivery Systems (NDDS), Drug Repurposing, Clinical Development, Intellectual Property Licensing
Stock Listing: NSE (SPARC), BSE (532872)
Promoter: Sun Pharmaceutical Industries Ltd. / Dilip Shanghvi
Incorporated in 2006 as an independent pharmaceutical research and development company, following a demerger from Sun Pharmaceutical Industries Ltd. The objective was to create a dedicated entity focused on innovation. Since its inception, SPARC has been engaged in discovering and developing new chemical entities and innovative drug delivery systems, building a pipeline primarily for its promoter group, Sun Pharma.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical Research & Development | 100% | N/A (Loss-making / Highly variable) |
Pharmaceutical Research & Development: Engaged in the discovery and development of novel chemical entities (NCEs) and innovative drug delivery systems (NDDS) across various therapeutic areas like oncology, neurology, dermatology, and ophthalmology.
Clinical Development: Conducts pre-clinical and clinical trials (Phase I, II, III) for its investigational products to assess safety and efficacy, often in collaboration with global partners and regulatory bodies.
Intellectual Property Management: Focuses on building a strong patent portfolio to protect its innovations, including new molecules, formulations, and processes, and engages in licensing activities.
Dilip Shanghvi: Chairman and Managing Director. Founder of Sun Pharmaceutical Industries Ltd. and a visionary leader in the Indian pharmaceutical sector with extensive experience in drug discovery and business strategy. Anil Kumar Raina: CEO. A seasoned pharmaceutical professional with over two decades of experience, having previously held senior leadership roles within the Sun Pharma Group.
SPARC Inc. (USA)
SPARC Specialty Inc. (USA)
Sun Pharma Advanced Research Company (Ireland) Limited
2021: Rights Issue (4 shares for every 25 held, at ₹250 per share including a premium of ₹249).
The Sun Pharma Advanced Research Company Ltd share price today is ₹196.98 on NSE (SPARC), as of 14 Sept 2026.
As of 01 Sept 2026, Sun Pharma Advanced Research Company Ltd share price is ₹196.98, with previous close ₹196.98. Today's range is ₹196.98 to ₹196.98. The 52-week range is ₹196.98 to ₹196.98.
As of today, Sun Pharma Advanced Research Company Ltd's market cap is ₹5,885.76 crore (Mid Cap).
Sun Pharma Advanced Research Company Ltd's current P/E ratio is 4.12, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 33.50.
Sun Pharma Advanced Research Company Ltd's current P/B ratio is 4.77.
Sun Pharma Advanced Research Company Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Sun Pharma Advanced Research Company Ltd's EPS (TTM) is ₹553.65.
Sun Pharma Advanced Research Company Ltd (SPARC) is a pure-play pharmaceutical R&D company focused on discovering and developing novel chemical entities (NCEs) and innovative drug delivery systems (NDDS). It leverages advanced scientific approaches to create differentiated products, primarily for its promoter, Sun Pharmaceutical Industries Ltd., aiming to address unmet medical needs.
Sun Pharma Advanced Research Company Ltd is promoted by Sun Pharmaceutical Industries Ltd. / Dilip Shanghvi, holding 65.67% as of 01 Sept 2026.
Sun Pharma Advanced Research Company Ltd is listed on NSE (SPARC) and BSE (532872). Its next quarterly results are expected on October 2024 (for Q2 FY25).